YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
ANI Pharmaceuticals recently received final U.S. FDA approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension 2mg, 3mg, and 5mg, the generic version of Afinitor Disperz, entering a U.S. market with appro…
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn Down Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Luckily for y…
1 Small-Cap Stock for Long-Term Investors and 2 We Ignore Investors looking for hidden gems should keep an eye on small-cap stocks because they're frequently overlooked by Wall Street. Many opportunities exist in this part of the market, b…
ANI Pharmaceuticals, Inc. Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026 Post-hoc analyses of baseline characteristics and efficacy o…
3 Profitable Stocks Worth Investigating Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline. Even among profitable busine…
Investors in ANI Pharmaceuticals, Inc. ANIP need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 16, 2026 $40.00 Put had some of the highest implied volatility of all equity options…
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid…
ANI Pharmaceuticals, Inc. PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) fo…
2 Cash-Producing Stocks to Target This Week and 1 We Avoid While strong cash flow is a key indicator of stability, it doesn't always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing dema…
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthu…
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX) Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generi…
2 Value Stocks on Our Watchlist and 1 We Find Risky The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinel…
2 Reasons to Like ANIP (and 1 Not So Much) ANI Pharmaceuticals currently trades at $76.15 per share and has shown little upside over the past six months, posting a middling return of 3%. The stock also fell short of the S&P 500's 11.7% gai…
1 Russell 2000 Stock to Target This Week and 2 We Brush Off Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger…
ANI Pharmaceuticals, Inc. – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: AN…
The Top 5 Analyst Questions From ANI Pharmaceuticals's Q2 Earnings Call ANI Pharmaceuticals' second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively to the resu…
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sect…
ANI Pharmaceuticals, Inc. ANIP presents a sharp valuation-versus-execution trade-off. The stock trades at a steep discount to key benchmarks even as consensus forecasts point to double-digit sales and earnings growth in 2026. Cortrophin Ge…
ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight…
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 2…
ANI Pharmaceuticals ANIP reported second-quarter 2026 adjusted EPS of $2.21, beating the Zacks Consensus Estimate of $2.01. The reported figure rose 23% year over year, driven by higher sales during the quarter. Quarterly revenues totaled…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ANI Pharmaceuticals earnings beat and guidance reset ANI Pharmaceuticals (ANIP) reported better than expected Q2 2026 results and r…
ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Transformation and Operational Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why…
This article first appeared on GuruFocus. Release Date: August 07, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Record Q2 2026 revenues of $266 million, up 26% ye…
For the quarter ended June 2026, ANI Pharmaceuticals (ANIP) reported revenue of $266.04 million, up 25.9% over the same period last year. EPS came in at $2.21, compared to $1.80 in the year-ago quarter. The reported revenue compares to the…
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.8 per share a year ago. These figures are adjusted for non-recurring i…
ANI Pharmaceuticals's (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results topping the market's revenue expectations , w…
ANI Pharmaceuticals, Inc. Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to com…
Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-yearPurified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5% year-over-yearQuarterly GAAP net income available to common shareholders of $24.7 mi…
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.72 per share a year ago. These figures are adjusted for non-recurring i…
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring i…
Ovid Therapeutics (OVID) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earning…
1 Healthcare Stock Worth Your Attention and 2 We Question From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong finan…
TG Therapeutics (TGTX) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring item…
The market expects ANI Pharmaceuticals (ANIP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the co…
The market expects ANI Pharmaceuticals (ANIP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the co…